The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the life science realm.
…
continue reading
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss CG Oncology, the first biotech IPO of 2024. We dive into: The various subtypes of bladder cancer, and one of the most uniq…
…
continue reading
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Ketan Yerneni and Mack Healy discuss Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. We dive…
…
continue reading
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Patrick Malone and Mack Healy discuss the biopharma software juggernaut, Schrödinger. We dive into: Schrödinger's biophysics-based drug discovery platform, and t…
…
continue reading
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss: the mechanism of action of Amylyx’s lead disease-modify…
…
continue reading
KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Codiak BioSciences.
…
continue reading
KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Royalty Pharma.
…
continue reading
KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Sana Biotechnology.
…
continue reading
KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Editas.
…
continue reading
KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Century Therapeutics.
…
continue reading
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Taysha GTx
…
continue reading
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, Atai
…
continue reading
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, Recursion Pharmaceuticals.
…
continue reading
The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, AbCellera.
…
continue reading